We are live on ! Find out more
VIVO

Meridian Bioscience Inc

Delisted

VIVO was delisted on the 30th of January, 2023.

192 hedge funds and large institutions have $732M invested in Meridian Bioscience Inc in 2020 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 69 increasing their positions, 59 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more call options, than puts

Call options by funds: $2.71M | Put options by funds: $1.73M

17% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 59

11% more capital invested

Capital invested by funds: $657M → $732M (+$75.2M)

8% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 26

1% more funds holding

Funds holding: 191192 (+1)

Holders
192
Holders Change
+1
Holders Change %
+0.52%
% of All Funds
3.4%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
28
Increased
69
Reduced
59
Closed
26
Calls
$2.71M
Puts
$1.73M
Net Calls
+$980K
Net Calls Change
-$74K
Name Holding Trade Value Shares
Change
Change in
Stake
QI
126
QS Investors
New York
$313K
MSA
127
Mason Street Advisors
Wisconsin
$300K -$336 -18 -0.1%
State of Wisconsin Investment Board
128
State of Wisconsin Investment Board
Wisconsin
$293K -$78.4K -4,200 -21%
Mariner
129
Mariner
Kansas
$282K +$41.7K +2,231 +17%
Bank of Montreal
130
Bank of Montreal
Ontario, Canada
$275K +$131K +7,029 +128%
JF
131
Jump Financial
Illinois
$271K +$271K +14,496 New
BCI
132
Brinker Capital Investments
Pennsylvania
$267K -$653K -34,960 -71%
Russell Investments Group
133
Russell Investments Group
United Kingdom
$265K -$1.62M -86,604 -86%
Osaic Holdings
134
Osaic Holdings
Arizona
$261K +$33.6K +1,800 +15%
MLICM
135
Metropolitan Life Insurance Company (MetLife)
New York
$261K
Ensign Peak Advisors
136
Ensign Peak Advisors
Utah
$260K +$260K +13,900 New
ECM
137
ExodusPoint Capital Management
New York
$257K +$256K +13,725 New
6M
138
6 Meridian
Kansas
$244K +$6.09K +326 +3%
BNP Paribas Financial Markets
139
BNP Paribas Financial Markets
France
$243K +$38.7K +2,070 +19%
ECM
140
Everence Capital Management
Indiana
$242K
ASRS
141
Arizona State Retirement System
Arizona
$232K -$9.09K -487 -4%
LIA
142
LS Investment Advisors
Michigan
$216K +$216K +11,568 New
CAM
143
Cozad Asset Management
Illinois
$207K
WG
144
Winton Group
United Kingdom
$206K +$206K +11,015 New
Public Employees Retirement Association of Colorado
145
Public Employees Retirement Association of Colorado
Colorado
$195K
FIM
146
Freedom Investment Management
Connecticut
$191K -$91.5K -4,902 -32%
ProShare Advisors
147
ProShare Advisors
Maryland
$191K +$191K +10,204 New
CBB
148
Citizens Business Bank
California
$187K
AA
149
Ancora Advisors
Ohio
$170K -$30.6K -1,640 -15%
PI
150
PEAK6 Investments
Illinois
$153K +$32.9K +1,761 +27%

VIVO Hedge Fund Activity: Q4 2020 in Review

192 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q4 2020, worth a combined $732M — up 11% from $657M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new VIVO positions and 26 closed out — a net gain of 2 holders — while 69 added to existing stakes and 59 trimmed.

The largest buyer was Deerfield Management, adding an estimated $12.2M. The largest seller was Kennedy Capital Management, exiting entirely with an estimated $9.47M sold.

  • 192 institutional investors held Meridian Bioscience Inc (VIVO) as of Q4 2020, up from 191 in Q3 2020.
  • Funds reported $732M of Meridian Bioscience Inc stock for Q4 2020, up 11% quarter-over-quarter.
  • 28 funds opened new Meridian Bioscience Inc positions in Q4 2020 and 26 closed out, a net change of +2 holders.
  • The largest Meridian Bioscience Inc buyer in Q4 2020 was Deerfield Management, an estimated $12.2M added.
  • The largest Meridian Bioscience Inc seller in Q4 2020 was Kennedy Capital Management, an estimated $9.47M sold.

Based on aggregated 13F filings for Q4 2020.